Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.54 |
| ▸ | FLT3 | P36888 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | FLT4 | P35916 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.45 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703897 | 1.00 | CSF1R (0.54) | CSF1RFLT3KDRFLT4KIT | |
| SCHEMBL4758071 | 0.95 | CSF1R (0.52) | CSF1RFLT3KDRFLT4KIT | |
| SCHEMBL4706778 | 0.95 | CSF1R (0.52) | CSF1RFLT3KDRFLT4KIT | |
| SCHEMBL4759327 | 0.94 | CSF1R (0.56) | CSF1RFLT3KDRFLT4KIT | |
| SCHEMBL4703036 | 0.94 | CSF1R (0.56) | CSF1RFLT3KDRFLT4KIT | |
| SCHEMBL4757095 | 0.94 | NTRK1 (0.50) | CSF1RFLT3NTRK1NTRK3AURKB | |
| SCHEMBL4757094 | 0.94 | NTRK1 (0.50) | CSF1RFLT3NTRK1NTRK3AURKB | |
| SCHEMBL4755255 | 0.93 | CSF1R (0.54) | CSF1RFLT3KDRFLT4KIT | |
| SCHEMBL4755254 | 0.93 | CSF1R (0.54) | CSF1RFLT3KDRFLT4KIT | |
| SCHEMBL4757149 | 0.92 | CSF1R (0.53) | CSF1RFLT3KDRFLT4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | CSF1R 877/4885FLT3 87/4885KDR 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.